ACR 0.00% 5.4¢ acrux limited

vivus calls it quits on testosterone drug

  1. 366 Posts.
    Daunted by the prospect of a lengthy safety review, Mountain View, CA-based Vivus is giving up on its program for an experimental testosterone therapy for women. The developer says it is shelving the Luramist program and returning the rights to a subsidiary of Acrux. "The decision to terminate the agreement was made in view of the significant long-term safety requirements for the approval of testosterone products in women," stated Peter Tam, president of Vivus, in a prepared statement. "We believe it is in our shareholders' best interests to pursue other therapeutic candidates." Tam plans to focus the company on its two leading therapies: Qnexa for obesity and avanafil for erectile dysfunction.


    ***

    Set back for Acrux or an opportunity to renegotiate the female equivilent of Axiron in light of the massive deal?

    Seems a waste of time for Acrux to have to now find a new party - hopefully Lilly will be interested. I wonder if there are any details as to contractual relief for this?
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
(20min delay)
Last
5.4¢
Change
0.000(0.00%)
Mkt cap ! $15.69M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 434 5.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.8¢ 17258 1
View Market Depth
Last trade - 16.12pm 04/10/2024 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.